Stem-cell transplantation for autoimmune diseases.
The use of intensive immunosuppressive treatment coupled with BM stem-cell transplantation (SCT) to treat human autoimmune diseases (AID) follows anecdotal observations of responses of AID to allogeneic SCT and an extensive background of experience with SCT in animals with AID. In the last decade, numerous clinical trials have been initiated to explore a potential benefit of (mainly autologous) SCT in advanced and debilitating cases of rheumatoid arthritis, scleroderma, systemic lupus erythematosis and multiple sclerosis. In this review the etiology of AID and the experimental basis of SCT is presented, together with recent clinical results of SCT for AID. While much has been learned about the risks and benefits of SCT in AID, the underlying mechanisms regulating remission and relapse of AID after treatment remain largely unknown.
Scheinberg
P
P
Hematology Branch National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
D001327:Autoimmune Diseases / Q000209:etiology / Q000628:therapy*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000628:therapy; D009103:Multiple Sclerosis / Q000628:therapy; D045743:Scleroderma, Diffuse / Q000276:immunology / Q000628:therapy; D033581:Stem Cell Transplantation